References
- Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramirez, C., Sabate, M., Jimenez-Quevedo, P., Macaya, C. (2005). Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes,54 (8), 2430–2435.
- Badimon, L., Padró, T., Vilahur, G. (2012). Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur. Heart J. Acute Cardiovasc. Care, 1 (1), 60–74.
- Balucani, C., Barlinn, K., Zivanovic, Z., Parnetti, L., Silvestrini, M., Alexandrov, A. V. (2010). Dual antiplatelet therapy in secondary prevention of ischemic stroke: A ghost from the past or a new frontier? Stroke Res. Treat., DOI 2010:427418.
- Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., et al. (2001). Cyclooxygenase inhibitors and the antiplateleteffects of aspirin. New Engl. J. Med.,345, 1809–1817.
- Feher, G., Feher, A., Pusch, G., et al. (2010). Clinical importance of aspirin and clopidogrel resistance. World J. Cardiol., 2 (7), 171–186.
- Feher, G., Feher, A., Pusch, G., Lupkovics, G., Szapary, L., Papp, E. (2009). The genetics of antiplatelet drug resistance. Clin. Genet.,75 (1), 1–18.
- Ferreira, I. A., Mocking, A. I., Feijge, M. A., et al. (2006). Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol.,26, 417–422.
- Fiolaki, A., Katsanos, A. H., Kyritsis, A. P., Papadaki, S., Kosmidou, M., Moschonas, I. C. Giannopoulos, S. (2017). High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis. J. Neurol. Sci., 376, 112–116.
- Freedman, J. E., Hylek, E. M. (2009). Clopidogrel, genetics, and drug responsiveness. New Engl. J. Med.,360 (4), 411–413.
- Goodman, T., Ferro, A., Sharma, P. (2008). Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Brit. J. Clin. Pharmacol., 66 (2), 222–232.
- Gurbel, P. A., Tantry, U. S. (2007). Clopidogrel resistance? Thrombosis Res., 120 (3), 311–321.
- Karepov, V., Tolpina, G., Kuliczkowski, W., Serebruany, V. (2008). Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. Cerebrovas. Dis., 26 (3), 272–276.
- Krasopoulos, G., Brister, S. J., Beattie,W. S., Buchanan, M. R. (2008). Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ,336, 195–198.
- Mansour, K., Taher, A. T., Musallam, K. M., Alam, S. (2009). Aspirin resistance. Adv. Hematol. 10.1155/2009/937352. Available from: https://www.ncbi.nlm.nih.gov/pubmed/19960045 (accessed 15.05.2019).
- Motovská, Z., Varvarovský, I., Ostádal, P. (2017). ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Summary of the document prepared by the Czech Society of Cardiology. Cor et Vasa, 59 (6), e592–e612.
- Poulsen, T. S., Jorgensen, B., Korsholm, L., et al. (2017). Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb. Res.,119, 555–562.
- Jones, R., Arps, K., Davis, D. M., Blumenthal, R., Martin, S. S. (2018). Clinician Guide to the ABCs of Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease. Available from: https://www.acc.org/latest-in-cardiology/articles/2018/03/30/18/34/clinician-guide-to-the-abcs (accessed 15.05.2019).
- Simon, T., Verstuyft, C., Mary-Krause, M., et al. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. New Engl. J. Med.,360 (4), 363–375.
- Snoep, J. D., Hovens, M. M., Eikenboom, J. C., van der Bom, J. G., Jukema, J. W., Huisman, M. V. (2007). Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Amer. Heart J., 154, 221–231.
- Wang, C. B., Hu, D. Y., Shi, X. B., et al. (2006). Aspirin resistance in patients taking small dose of aspirin. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 18, 219–223.
- Wang, T. H., Bhatt, D. L., Topol, E. J. (2005). Aspirin and clopidogrel resistance: An emerging clinical entity. Eur. Heart J., 27 (6), 647–654.
- Weber, A. A., Zimmerman, K. C., Meyer-Kirchrath, J, Schor, K. (1999). Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet,353, 900.
- Wong, K. S. L., Wang, Y., Leng, X., Mao, C., Tang, J., Bath, P. M. W., Wang, Y. (2013). Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack. Circulation, 128 (15), 1656–1666.
- Zimmermann, N., Wenk, A., Kim, U., Kienzle, P., Weber, A.-A., Gams, E., Schror, K., Hohlfeld, T. (2003). Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation,108, 542–547.